Your browser doesn't support javascript.
loading
Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing.
Zumbrun, Elizabeth E; Garvey, Carly B; Wells, Jay B; Lynn, Ginger C; Van Tongeren, Sean; Steffens, Jesse T; Wetzel, Kelly S; Gomba, Laura M; O'Brien, Kristan A; Rossi, Franco D; Zeng, Xiankun; Lee, Eric D; Raymond, Jo Lynne W; Hoffman, Diana A; Jay, Alexandra N; Brown, Elizabeth S; Kallgren, Paul A; Norris, Sarah L; Cantey-Kiser, Jean; Kudiya, Humza; Arthur, Chris; Blair, Christiana; Babusis, Darius; Chu, Victor C; Singh, Bali; Bannister, Roy; Porter, Danielle P; Cihlar, Tomas; Dye, John M.
Affiliation
  • Zumbrun EE; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Garvey CB; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Wells JB; Geneva Foundation, Tacoma, WA 98402, USA.
  • Lynn GC; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Van Tongeren S; Geneva Foundation, Tacoma, WA 98402, USA.
  • Steffens JT; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Wetzel KS; Geneva Foundation, Tacoma, WA 98402, USA.
  • Gomba LM; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • O'Brien KA; Geneva Foundation, Tacoma, WA 98402, USA.
  • Rossi FD; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Zeng X; Geneva Foundation, Tacoma, WA 98402, USA.
  • Lee ED; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Raymond JLW; Geneva Foundation, Tacoma, WA 98402, USA.
  • Hoffman DA; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Jay AN; Geneva Foundation, Tacoma, WA 98402, USA.
  • Brown ES; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Kallgren PA; Geneva Foundation, Tacoma, WA 98402, USA.
  • Norris SL; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Cantey-Kiser J; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Kudiya H; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Arthur C; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Blair C; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Babusis D; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Chu VC; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Singh B; Geneva Foundation, Tacoma, WA 98402, USA.
  • Bannister R; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Porter DP; United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Cihlar T; PharPoint, Wilmington, NC 28405, USA.
  • Dye JM; Gilead Sciences, Foster City, CA 94404, USA.
Viruses ; 15(12)2023 11 28.
Article in En | MEDLINE | ID: mdl-38140576
ABSTRACT
Marburg virus (MARV) causes severe disease and high mortality in humans. The objective of this study was to characterize disease manifestations and pathogenesis in cynomolgus macaques exposed to MARV. The results of this natural history study may be used to identify features of MARV disease useful in defining the ideal treatment initiation time for subsequent evaluations of investigational therapeutics using this model. Twelve cynomolgus macaques were exposed to a target dose of 1000 plaque-forming units MARV by the intramuscular route, and six control animals were mock-exposed. The primary endpoint of this study was survival to Day 28 post-inoculation (PI). Anesthesia events were minimized with the use of central venous catheters for periodic blood collection, and temperature and activity were continuously monitored by telemetry. All mock-exposed animals remained healthy for the duration of the study. All 12 MARV-exposed animals (100%) became infected, developed illness, and succumbed on Days 8-10 PI. On Day 4 PI, 11 of the 12 MARV-exposed animals had statistically significant temperature elevations over baseline. Clinically observable signs of MARV disease first appeared on Day 5 PI, when 6 of the 12 animals exhibited reduced responsiveness. Ultimately, systemic inflammation, coagulopathy, and direct cytopathic effects of MARV all contributed to multiorgan dysfunction, organ failure, and death or euthanasia of all MARV-exposed animals. Manifestations of MARV disease, including fever, systemic viremia, lymphocytolysis, coagulopathy, and hepatocellular damage, could be used as triggers for initiation of treatment in future therapeutic efficacy studies.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Marburgvirus / Marburg Virus Disease Limits: Animals / Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Marburgvirus / Marburg Virus Disease Limits: Animals / Humans Language: En Year: 2023 Type: Article